This January and February, Bio-Techne presents a series of conference-level talks based on key advances in Bioconjugation.
Join us on 24th February at 1pm GMT for the last of 3 exceptional presentations by established speakers in the field. You can listen to the first event in this series, by Dr Richards, by clicking here. The second event, hosted by Dr Chudasama, can be found here.
During this third and final session, Dr João Nunes will talk about Antibody-Drug Conjugates (ADCs). ADCs are a class of targeted drugs for oncology. The number of FDA approved ADCs has recently skyrocketed and interest in developing ADCs is on an upwards trajectory. This webinar will summarise the design choices for linker-payloads in the current selection of FDA approved ADCs and how they inform on developability for the next generation of ADCs.
Bio-Techne empowers researchers in Life Science and Clinical Diagnostics by providing high-quality reagents, instruments, custom manufacturing, and testing services. Science is our passion; it drives us to collaborate, develop, and manufacture award-winning tools that help researchers achieve reproducible and consistent results. Let us help you achieve success.
Dr João P. M. Nunes is a Senior Scientist at Abzena, a life sciences group with its headquarters in San Diego, California which provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and ADC drug development services in the pharmaceutical industry. He specialises in conjugation of cytotoxic drugs to antibodies for development of early drug discovery antibody-drug conjugates and has co-authored 17 scientific publications. Dr João P. M. Nunes holds a PhD in Organic Chemistry, having developed two methods for the synthesis of bifunctionalised cyclopentenones and synthesised over 40 novel compounds. He had over 15 years of research across multiple projects in Bioconjugation, Organic Chemistry and Coordination Chemistry.
Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.
Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.